Oral Factor Xa inhibitors
Cross-source consensus on Oral Factor Xa inhibitors from 1 sources and 4 claims.
1 sources · 4 claims
How it works
Comparisons
Evidence quality
Highlighted claims
- Dabi-SNAP compares switching to dabigatran against continuing the currently prescribed oral FXa inhibitor. — Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial
- Oral FXa inhibitors share dabigatran's main clinical indications but target only Factor Xa. — Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial
- The article states that oral FXa inhibitors have no demonstrated direct effect on S. aureus coagulase or staphylothrombin virulence mechanisms. — Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial
- Population-level observational evidence suggested lower invasive S. aureus disease incidence among dabigatran users than oral FXa inhibitor users. — Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial